FLT-201 is under clinical development by Freeline Therapeutics Holdings and currently in Phase II for Gaucher Disease Type I. According to GlobalData, Phase II drugs for Gaucher Disease Type I have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FLT-201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FLT-201 overview

FLT-201 is under development for the treatment of type 1 Gaucher disease. The drug candidate is administered through intravenous route. It comprises of adeno-associated virus (AAV) vector encoding GBA1 gene. The drug candidate is developed based on next-generation proprietary AAV vector platform.

Freeline Therapeutics Holdings overview

Freeline Therapeutics Holdings Plc (Freeline), a subsidiary of Syncona Ltd, is a biotechnology company that develops transformative gene therapies for treatment of debilitating diseases. The company utilizes AAV vector and AAVS3 platform to deliver functional copy of therapeutic gene into human liver cells. Its platform consists of in-house capabilities in research and clinical development. Freeline’s product pipeline includes FLT190, a liver directed gene therapy to treat fabry disease; and FLT201 for treatment of gaucher disease. The company works along with clinicians, researchers, and companies worldwide. It serves pharmaceutical and healthcare sectors. The company operates in Germany, and the US. Freeline is headquartered in Stevenage, the UK.

For a complete picture of FLT-201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.